Maria Sainz was appointed President & CEO of AEGEA Medical in May 2018. She has over 25 years’ experience in commercial and leadership positions in the medtech industry. Maria has served as the President & CEO of Cardiokinetix, a medical device company pioneering a catheter-based treatment for heart failure. Prior to that, Maria was the President & CEO of Concentric Medical, Inc., a developer of minimally invasive products for the treatment of acute ischemic stroke which was acquired in 2011 by Stryker Corporation. Maria began her medtech career at Guidant Corporation where she held positions of increasing responsibility in Europe and the US. At the time of the acquisition of Guidant by Boston Scientific, Maria served as President of the Cardiac Surgery division of Guidant Corporation. Maria has been intimately involved in several major medtech product launches such as coronary stents or cardiac resynchronization therapy devices. Maria also serves as a Director of several public and private medical company boards. She received a M.A in Languages from the University Complutense in Madrid, Spain and a Masters in International Management from the American Graduate School of International Management.
Don Gurskis - Chief Technology Officer
Don brings more than 20 years of device development and leadership experience. In addition to a track record of building and directing highly effective teams, Don has held key roles taking products from inception, though device development, clinical trials, and then successfully into commercialization. Don has extensive experience directly helping transform women’s healthcare with key innovation and leadership roles at all stages for Conceptus (acquired by Bayer AG). More recent activity includes serving as VP of R&D leading both heart valve replacement prosthetics and minimally invasive implantation programs at Arbor Surgical Technologies (acquired by Medtronic). Don is a named inventor on 55 issued US patents. Don has a B.S. in Biomedical Engineering from University of California, San Diego.
Hiram Chee - Executive Vice President, Research & Development
Hiram is responsible for design and development. He has over 30 years of broad operations and management experience in the medical device industry. Previously, Hiram was a consultant for start-up medical device companies responsible for development of a variety of disposable and implantable devices from concept through clinical evaluations, manufacturing scale-up and commercialization. He was Chief Operating Officer at Tautona Group, LLC, a private equity fund and incubator focused on wound healing, reconstructive and aesthetic surgery. Hiram was Executive Vice President at Spinal Kinetics, Inc. a venture-backed company developing and commercializing implants for the spine where he led product development, manufacturing, quality assurance, regulatory, and clinical affairs. He was Entrepreneur-in-Residence at US Venture Partners where he developed novel product concepts and conducted investment diligence. Hiram was Vice President, Research and Development and Operations, at MicroHeart, a startup that developed devices and pharmaceuticals to treat cardiovascular disease, acquired by Boston Scientific. He was Vice President Peripheral Vascular and Vice President, Research and Development at Target Therapeutics, a publicly traded company that developed intravascular devices to treat stroke and diseases in remote areas of the body, acquired by Boston Scientific and later acquired by Stryker.
Hiram received a B.S. in Chemical Engineering from the University of California, San Diego and a Certificate in Biomedical Engineering from the University of California, Irvine. Hiram is named inventor in over 50 issued US patents.
Hugh Magen - Vice President, Research & Development
Hugh leads the development of the reusable Controller and the system integration. Hugh has over 20 years in the medical device field. He has a broad range of experience, having developed implants for women’s health, cardiology, urology and orthopedics, as well as several energy delivery devices incorporating the modalities of RF energy, cryogen, and electromagnetics. Previously, Hugh was a consultant providing his expertise in research and design, project management, and company growth strategy to several early stage medical device start-ups. He was Sr. Director of R&D at Rubicor Medical, developing minimally invasive image-guided devices for breast cancer diagnosis and treatment procedures. At Stellartech Research Corporation, a provider of contract R&D and manufacturing services, Hugh was the lead engineer developing the Thermage Thermacool system. Additionally, Hugh held senior engineering roles at Coapt Systems and Vascular Therapies (US Surgical Corp [now Covidien]). Hugh received a BS in Aerospace Engineering from the University of Virginia and an MS in Biomedical Engineering from the University of California at Davis.
Alexis Dineen - Acting Vice President, Regulatory Affairs
Alexis is a regulatory affairs professional with over 30 years of experience in the start-up medical device company environment. She has a proven ability to drive the regulatory process, both as a direct employee and as a consultant. Her experience includes cardiovascular and gynecological device regulatory approvals, helping to grow companies from early start-up to viable companies. She developed and implemented regulatory and clinical strategies for multiple successful device approvals, three of which were novel first-of-a-kind devices. Past clients include Evalve, Inc. (acquired by Abbott Vascular), Asthmatx (acquired by Boston Scientific), Cierra, Inc and numerous other start-up device companies. Prior to working as a consultant, Alexis worked at the Foundry, LLC as Vice President of Clinical Research and Regulatory Affairs. Before that, she held positions including Vice President, Clinical Research and Regulatory Affairs at EMBOL-X, Inc. (acquired by Edwards Lifesciences), Director of Clinical Research and Regulatory Affairs at Conceptus, Inc. (public and later acquired by Bayer AG) where she was a Charter Member of the company, and various Clinical Research and Regulatory Affairs positions with increasing responsibility at Target Therapeutics, Inc. (a public company, acquired by Boston Scientific and later by Stryker). Alexis holds a Bachelors degree in Organizational Psychology from the University of California, Santa Barbara.
Thomas Kelly - Vice President, Operations & Quality Assurance
Thomas brings to AEGEA a strong combination of management skills in Operations and Quality Assurance gained through 25 years in the medical device industry. Before joining AEGEA he was Vice President of Operations & Quality at ForSight VISION4, a startup company developing an ocular implant to facilitate sustained drug therapy; the company was acquired by Genentech. Prior to ForSight, Thomas served as Vice President of Operations and Quality at Arstasis. He implemented and managed the Operations and Quality functions, growing the femoral access technology from pre-clinical to FDA 510k and CE approval through market launch. At Cierra, Thomas implemented and managed the QA function as Director of Quality Assurance leading to ISO 13485 certification and achievement of the CE Mark for the Patent Foramen Ovale closure device. Thomas worked for Perclose developing arterial closure devices, contributing to the company’s growth from a small, pre-clinical startup to a successful publicly traded company, followed by acquisition into Abbott Laboratories. He contributed in several areas, developing a solid foundation in Quality Assurance, Manufacturing Engineering, and Research and Development. He headed cross-functional product development and manufacturing transfer teams for new products, including integration of an acquired technology, through market launch. Thomas started his medical device career with Stryker Corporation’s Endoscopy division in Quality Assurance. Thomas holds a B.S. in Manufacturing Engineering from Oregon State University.
Natalie Shlafman - Vice President, Marketing
Natalie Shlafman brings over 20 years of marketing, commercialization and leadership experience. Prior to joining AEGEA, Natalie had been a consultant who worked with a diverse set of medical technology companies. She served as an interim marketing leader and advisor and drove market assessment and research, marketing strategy and execution, marketing communications and product launches. Before consulting, Natalie was the Vice President of Marketing at CardioDx, a cardiovascular genomic diagnostics company. During her tenure, she built out and directed the company’s marketing capabilities and drove all commercially-related aspects of developing, launching and driving adoption for the company’s flagship product. Prior to CardioDX, Natalie was in the Vascular Intervention Division of Guidant Corporation where she worked in market development within the New Ventures unit and in product marketing within the Angioplasty Systems group. Natalie started her career in the high-tech industry and held product marketing roles at LogicTier and at SGI. Natalie received her M.B.A. from Kellogg School of Management at Northwestern University and her B.A in psychology with a business specialization from UCLA.
Micah Harris, M.D. - Medical Director
Micah Harris, M.D., F.A.C.O.G. has been conducting clinical research trials through Women’s Health Research Ltd. for more than 20 years. Dr. Harris is a board certified Obstetrician/Gynecologist and he holds a medical degree from the University of South Florida College of Medicine. He completed his postgraduate training at the University of South Florida in Tampa, Florida. Dr. Harris’ research has been published in the Journal of Minimally Invasive Gynecology; Obstetrics and Gynecology; and the Journal of Reproductive Medicine. He has served as an investigator for over 100 clinical trials, many involving endometrial ablation technologies, and including those commercially available endometrial ablation devices approved by the FDA.
John Beck - Acting Chief Financial Officer
John started BeckCFO in 2007 and brings over 30 years of experience in financial management, strategic planning and execution for technology firms. John has worked with early stage companies in life sciences (medical device and pharmaceutical), fabless semiconductor, software and software as a service, hardware systems, and services. John has held full-time CFO positions with both public and private companies, and, in addition to finance, has broad experience managing cross-functional areas such as IP management, legal, treasury, risk management, HR, IT and facilities. John’s background also includes managing the accounting, finance and reporting requirements of European and Asian offices.
Before starting BeckCFO, John previously served as CFO for several companies including: Silicon Bandwidth, Inc., nDSP Corporation (acquired by PixelWorks), Sigma Designs, Inc., Augeo Software, Meta-Software, Inc. (acquired by Synopsys), Sellectek Incorporated, RayLAN Corporation, Optimem and Spectra Logic subsidiaries of Cipher Data Products, and Minton Company. Prior to his tenure at technology firms, John held senior audit positions at Ernst & Young and KPMG Peat Marwick certified public accounting firms.
John earned a B.S. degree in Commerce with an Accounting emphasis, cum laude, from Santa Clara University. He is also a licensed C.P.A. (inactive), with the State of California.
Important Safety Information:
The Mara Water Vapor Ablation System is indicated to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia due to benign causes for whom childbearing is complete. Pregnancy following the Mara procedure can be dangerous. The Mara procedure is not for those who have or suspect uterine cancer; have an active genital, urinary or pelvic infection; or an IUD. As with all surgical procedures, there are risks and considerations associated with the use of the Mara Water Vapor Ablation System. Please refer to the device labeling for a detailed discussion of the device’s intended use, relevant warnings, precautions, side effects, and contraindications.